SMT201400086B - Derivati chinazolin-4(3H)-one usati come inibitoridi PI3 chinasi - Google Patents

Derivati chinazolin-4(3H)-one usati come inibitoridi PI3 chinasi

Info

Publication number: SMT201400086B
Authority: SM; San Marino
Prior art keywords: quinazolin; kinase inhibitors; derivatives used; derivatives; kinase
Prior art date: 2009-10-19

Application number

SM201400086T

Other languages

English (en)

Italian (it)

Inventor

Kazuhiro Ito

Peter John Murray

John King-Underwood

George Hardy

Frederick Arthur Brookfield

Christopher John Brown

Original Assignee

Respivert Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-19

Filing date

2014-06-30

Publication date

2014-09-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41462531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201400086(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-06-30 Application filed by Respivert Ltd filed Critical Respivert Ltd

2014-09-08 Publication of SMT201400086B publication Critical patent/SMT201400086B/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Otolaryngology (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SM201400086T 2009-10-19 2014-06-30 Derivati chinazolin-4(3H)-one usati come inibitoridi PI3 chinasi SMT201400086B (it)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0918249.4A GB0918249D0 (en)	2009-10-19	2009-10-19	Compounds
PCT/EP2010/065746 WO2011048111A1 (en)	2009-10-19	2010-10-19	Compounds

Publications (1)

Publication Number	Publication Date
SMT201400086B true SMT201400086B (it)	2014-09-08

Family

ID=41462531

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SM201400086T SMT201400086B (it)	2009-10-19	2014-06-30	Derivati chinazolin-4(3H)-one usati come inibitoridi PI3 chinasi

Country Status (36)

Country	Link
US (4)	US8741909B2 (es)
EP (1)	EP2491037B1 (es)
JP (1)	JP5889792B2 (es)
KR (1)	KR101770616B1 (es)
CN (1)	CN102712645B (es)
AR (1)	AR078674A1 (es)
AU (1)	AU2010309832B2 (es)
BR (1)	BR112012009214A2 (es)
CA (1)	CA2777902C (es)
CL (1)	CL2012000981A1 (es)
CR (1)	CR20120264A (es)
CY (1)	CY1116057T1 (es)
DK (1)	DK2491037T3 (es)
EA (1)	EA020330B3 (es)
EC (1)	ECSP12011805A (es)
ES (1)	ES2477270T3 (es)
GB (1)	GB0918249D0 (es)
HK (1)	HK1173728A1 (es)
HR (1)	HRP20140599T1 (es)
IL (1)	IL219248A (es)
ME (1)	ME02064B (es)
MX (1)	MX2012004525A (es)
MY (1)	MY164731A (es)
NI (2)	NI201200061A (es)
NZ (2)	NZ599162A (es)
PE (1)	PE20121390A1 (es)
PH (1)	PH12012500620A1 (es)
PL (1)	PL2491037T3 (es)
PT (1)	PT2491037E (es)
RS (1)	RS53385B (es)
SI (1)	SI2491037T1 (es)
SM (1)	SMT201400086B (es)
TW (1)	TWI478923B (es)
UA (1)	UA108743C2 (es)
WO (1)	WO2011048111A1 (es)
ZA (1)	ZA201203662B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8198279B2 (en)	2007-12-19	2012-06-12	Institute Of Cancer Research: Royal Cancer Hospital (The)	Pyrido[2,3-b]pyrazin-8-substituted compounds and their use
GB0918249D0 (en)	2009-10-19	2009-12-02	Respivert Ltd	Compounds
BR112012018415A2 (pt)	2010-02-01	2020-08-04	Cancer Research Technology Limited	composto, composição, métodos de preparar uma composição e de tratamento, e, uso de um composto.
UY33337A (es)	2010-10-18	2011-10-31	Respivert Ltd	DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
PT2790705T (pt)	2011-12-15	2018-01-24	Novartis Ag	Utilização de inibidores da atividade ou função de pi3k
PL2834244T3 (pl)	2012-03-13	2017-01-31	Respivert Limited	Krystaliczne inhibitory kinaz PI3
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
JP6434416B2 (ja)	2012-11-08	2018-12-05	ライゼン・ファーマシューティカルズ・エスアー	ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物
JO3279B1 (ar) *	2013-03-15	2018-09-16	Respivert Ltd	مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز
AR095353A1 (es)	2013-03-15	2015-10-07	Respivert Ltd	Compuesto
KR20160026970A (ko)	2013-06-14	2016-03-09	싸이오서스 테라퓨틱스 엘티디.	유형 b 아데노바이러스에 대한 투여 요법 및 제형
EP3052485B1 (en)	2013-10-04	2021-07-28	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2015051241A1 (en)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
GB201320732D0 (en)	2013-11-25	2014-01-08	Cancer Rec Tech Ltd	Methods of chemical synthesis
GB201320729D0 (en)	2013-11-25	2014-01-08	Cancer Rec Tech Ltd	Therapeutic compounds and their use
EA201691872A1 (ru)	2014-03-19	2017-04-28	Инфинити Фармасьютикалз, Инк.	Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
GB201510197D0 (en)	2014-06-12	2015-07-29	Psioxus Therapeutics Ltd	Method of treating ovarian cancer
GEP20186934B (en)	2014-07-04	2018-12-10	Limited Lupin	Quinolizinone derivatives as pi3k inhibitors
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2017048702A1 (en)	2015-09-14	2017-03-23	Infinity Pharmaceuticals, Inc.	Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en)	2016-03-17	2017-09-21	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
KR102737185B1 (ko) *	2018-01-20	2024-12-05	선샤인 레이크 파르마 컴퍼니 리미티드	치환된 아미노피리미딘 화합물 및 이의 사용 방법
CN108516976B (zh) *	2018-04-27	2020-07-03	四川大学华西医院	一种7-脱氮嘌呤衍生物及其四元环超分子结构
WO2020058072A1 (en) *	2018-09-18	2020-03-26	Société des Produits Nestlé S.A.	Src inhibitor compounds for skeletal muscle modulation, methods and uses thereof
WO2022017371A1 (zh) *	2020-07-21	2022-01-27	中国医药研究开发中心有限公司	具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1204826B (it)	1986-03-04	1989-03-10	Chiesi Farma Spa	Composizioni farmaceutiche per inalazione
GB9501841D0 (en)	1995-01-31	1995-03-22	Co Ordinated Drug Dev	Improvements in and relating to carrier particles for use in dry powder inhalers
US6645466B1 (en)	1998-11-13	2003-11-11	Jago Research Ag	Dry powder for inhalation
ATE248170T1 (de)	1999-01-11	2003-09-15	Univ Princeton	Kinase-inhibitoren mit hoher affinität zur ziel detektion und ihre verwendung
HUP0200185A3 (en)	1999-03-05	2006-07-28	Chiesi Farma Spa	Improved powdery pharmaceutical compositions for inhalation
PE20011227A1 (es)	2000-04-17	2002-01-07	Chiesi Farma Spa	Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
IL152275A0 (en)	2000-04-25	2003-05-29	Icos Corp	Inhibitors of human phosphatidyl-inositol 3-kinase delta
US6667300B2 (en) *	2000-04-25	2003-12-23	Icos Corporation	Inhibitors of human phosphatidylinositol 3-kinase delta
US6608053B2 (en)	2000-04-27	2003-08-19	Yamanouchi Pharmaceutical Co., Ltd.	Fused heteroaryl derivatives
JP3649395B2 (ja)	2000-04-27	2005-05-18	山之内製薬株式会社	縮合ヘテロアリール誘導体
EP1217000A1 (en)	2000-12-23	2002-06-26	Aventis Pharma Deutschland GmbH	Inhibitors of factor Xa and factor VIIa
EP1578898A2 (en)	2001-07-13	2005-09-28	Virtual Drug Development, Inc.	Nad synthetase inhibitors and uses thereof
WO2003007955A2 (en)	2001-07-20	2003-01-30	Cancer Research Technology Limited	Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
EP1553947A4 (en)	2002-10-21	2006-11-29	Bristol Myers Squibb Co	QUINAZOLINONES AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS
CA2517888C (en)	2003-03-14	2012-05-01	Ono Pharmaceutical Co., Ltd.	Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
US7122557B2 (en)	2003-03-18	2006-10-17	Bristol-Myers Squibb Company	Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
CA2520121A1 (en)	2003-04-03	2004-10-21	Protein Design Labs, Inc.	Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
US7429596B2 (en)	2003-06-20	2008-09-30	The Regents Of The University Of California	1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
GB0316341D0 (en)	2003-07-11	2003-08-13	Glaxo Group Ltd	Pharmaceutical formulations
EP1661879A4 (en)	2003-08-04	2006-11-29	Ono Pharmaceutical Co	A DIPHENYL ETHER COMPOUND, PROCESS FOR THE PRODUCTION AND USE THEREOF
WO2005016348A1 (en)	2003-08-14	2005-02-24	Icos Corporation	Method of inhibiting immune responses stimulated by an endogenous factor
WO2005016349A1 (en)	2003-08-14	2005-02-24	Icos Corporation	Methods of inhibiting leukocyte accumulation
GB0326632D0 (en)	2003-11-14	2003-12-17	Jagotec Ag	Dry powder formulations
WO2005067901A2 (en)	2004-01-08	2005-07-28	Michigan State University	Methods for treating and preventing hypertension and hypertension-related disorders
CA2730540A1 (en)	2004-05-13	2005-12-01	Vanderbilt University	Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
CN102229609A (zh) *	2004-05-13	2011-11-02	艾科斯有限公司	作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮
WO2005117889A1 (en)	2004-05-25	2005-12-15	Icos Corporation	Methods for treating and/or preventing aberrant proliferation of hematopoietic
WO2005120511A1 (en)	2004-06-04	2005-12-22	Icos Corporation	Methods for treating mast cell disorders
RU2409565C2 (ru)	2004-09-13	2011-01-20	Оно Фармасьютикал Ко., Лтд.	Азотистые гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента
GB0425758D0 (en)	2004-11-23	2004-12-22	Vectura Ltd	Preparation of pharmaceutical compositions
CA2598409A1 (en)	2005-02-17	2006-08-24	Icos Corporation	Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
GB0525254D0 (en)	2005-12-12	2006-01-18	Jagotec Ag	Powder compositions for inhalation
CN101506211B (zh) *	2006-04-04	2013-05-22	加利福尼亚大学董事会	激酶拮抗剂
KR20130087054A (ko)	2006-04-04	2013-08-05	더 리젠트스 오브 더 유니이버시티 오브 캘리포니아	키나제 길항물질
JP2009537158A (ja)	2006-05-24	2009-10-29	バイエル・シエーリング・ファーマアクチエンゲゼルシャフト	免疫原性の減少を伴った高親和性ヒトおよびヒト化抗−α５β１インテグリン機能阻害抗体
JP2009542662A (ja)	2006-06-29	2009-12-03	シェーリングコーポレイション	置換二環系および置換三環系トロンビン受容体アンタゴニスト
GB0622818D0 (en)	2006-11-15	2006-12-27	Jagotec Ag	Improvements in or relating to organic compounds
US8362066B2 (en)	2006-11-17	2013-01-29	Treventis Corporation	Compounds and methods for treating protein folding disorders
US20090035306A1 (en)	2006-11-29	2009-02-05	Kalypsys, Inc.	Quinazolinone modulators of tgr5
WO2008104077A1 (en)	2007-02-28	2008-09-04	Methylgene Inc.	Small molecule inhibitors of protein arginine methyltransferases (prmts)
AR066477A1 (es) *	2007-05-09	2009-08-19	Novartis Ag	Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido
WO2008140750A1 (en)	2007-05-10	2008-11-20	Hydra Biosciences Inc.	Compounds for modulating trpv3 function
MY172151A (en)	2008-01-04	2019-11-14	Intellikine Llc	Certain chemical entities, compositions and methods
JP5731978B2 (ja) *	2008-09-26	2015-06-10	インテリカイン，エルエルシー	複素環キナーゼ阻害剤
WO2010059593A1 (en)	2008-11-18	2010-05-27	Intellikine, Inc.	Methods and compositions for treatment of ophthalmic conditions
US20110294803A1 (en)	2008-12-04	2011-12-01	Law Amanda J	Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
EP2379505A4 (en)	2008-12-05	2012-10-17	Designmedix Inc	CHLOROQUINES MODIFIED BY A MONOCYCLIC GROUP OR A FUSED CYCLE GROUP
US20110135655A1 (en) *	2009-01-13	2011-06-09	PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine;	Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
BRPI1012333A2 (pt)	2009-03-24	2016-03-29	Gilead Calistoga Llc	atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
BR112012002331A2 (pt)	2009-08-05	2019-09-24	Versitech Ltd	composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
GB0918249D0 (en)	2009-10-19	2009-12-02	Respivert Ltd	Compounds
CA2813096C (en)	2010-09-30	2019-10-29	Chiesi Farmaceutici S.P.A.	Use of magnesium stearate in dry powder formulations for inhalation
UY33337A (es) *	2010-10-18	2011-10-31	Respivert Ltd	DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
PL2834244T3 (pl)	2012-03-13	2017-01-31	Respivert Limited	Krystaliczne inhibitory kinaz PI3

2009
- 2009-10-19 GB GBGB0918249.4A patent/GB0918249D0/en not_active Ceased
2010
- 2010-10-18 TW TW099135360A patent/TWI478923B/zh not_active IP Right Cessation
- 2010-10-19 CA CA2777902A patent/CA2777902C/en not_active Expired - Fee Related
- 2010-10-19 PL PL10771416T patent/PL2491037T3/pl unknown
- 2010-10-19 JP JP2012534671A patent/JP5889792B2/ja not_active Expired - Fee Related
- 2010-10-19 WO PCT/EP2010/065746 patent/WO2011048111A1/en active Application Filing
- 2010-10-19 UA UAA201203872A patent/UA108743C2/ru unknown
- 2010-10-19 CN CN201080047955.2A patent/CN102712645B/zh not_active Expired - Fee Related
- 2010-10-19 SI SI201030660T patent/SI2491037T1/sl unknown
- 2010-10-19 PT PT107714164T patent/PT2491037E/pt unknown
- 2010-10-19 EA EA201270575A patent/EA020330B3/ru not_active IP Right Cessation
- 2010-10-19 MX MX2012004525A patent/MX2012004525A/es active IP Right Grant
- 2010-10-19 ES ES10771416.4T patent/ES2477270T3/es active Active
- 2010-10-19 NZ NZ599162A patent/NZ599162A/xx not_active IP Right Cessation
- 2010-10-19 BR BR112012009214A patent/BR112012009214A2/pt not_active IP Right Cessation
- 2010-10-19 AR ARP100103812A patent/AR078674A1/es unknown
- 2010-10-19 EP EP10771416.4A patent/EP2491037B1/en active Active
- 2010-10-19 PH PH1/2012/500620A patent/PH12012500620A1/en unknown
- 2010-10-19 KR KR1020127012826A patent/KR101770616B1/ko not_active Expired - Fee Related
- 2010-10-19 PE PE2012000506A patent/PE20121390A1/es not_active Application Discontinuation
- 2010-10-19 US US13/502,465 patent/US8741909B2/en not_active Expired - Fee Related
- 2010-10-19 AU AU2010309832A patent/AU2010309832B2/en not_active Ceased
- 2010-10-19 RS RS20140344A patent/RS53385B/en unknown
- 2010-10-19 DK DK10771416.4T patent/DK2491037T3/da active
2011
- 2011-10-18 NZ NZ609147A patent/NZ609147A/en not_active IP Right Cessation
- 2011-10-18 MY MYPI2013700611A patent/MY164731A/en unknown
- 2011-10-18 ME MEP-2015-43A patent/ME02064B/me unknown
2012
- 2012-04-17 EC ECSP12011805 patent/ECSP12011805A/es unknown
- 2012-04-18 NI NI201200061A patent/NI201200061A/es unknown
- 2012-04-18 CL CL2012000981A patent/CL2012000981A1/es unknown
- 2012-04-18 IL IL219248A patent/IL219248A/en not_active IP Right Cessation
- 2012-05-18 ZA ZA2012/03662A patent/ZA201203662B/en unknown
- 2012-05-21 CR CR20120264A patent/CR20120264A/es unknown
2013
- 2013-01-18 HK HK13100837.2A patent/HK1173728A1/xx not_active IP Right Cessation
- 2013-04-16 NI NI201300035A patent/NI201300035A/es unknown
2014
- 2014-03-20 US US14/220,650 patent/US9321773B2/en not_active Expired - Fee Related
- 2014-06-26 HR HRP20140599AT patent/HRP20140599T1/hr unknown
- 2014-06-30 SM SM201400086T patent/SMT201400086B/xx unknown
- 2014-07-29 CY CY20141100570T patent/CY1116057T1/el unknown
2016
- 2016-03-31 US US15/086,120 patent/US9834560B2/en not_active Expired - Fee Related
2017
- 2017-11-08 US US15/806,742 patent/US20180118754A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NI201200061A (es)	2013-05-15
US20120208799A1 (en)	2012-08-16
US20160264583A1 (en)	2016-09-15
US8741909B2 (en)	2014-06-03
TWI478923B (zh)	2015-04-01
PT2491037E (pt)	2014-07-11
CR20120264A (es)	2013-01-25
PL2491037T3 (pl)	2014-09-30
AR078674A1 (es)	2011-11-23
KR101770616B1 (ko)	2017-08-23
WO2011048111A1 (en)	2011-04-28
NZ609147A (en)	2014-03-28
RS53385B (en)	2014-10-31
CN102712645A (zh)	2012-10-03
TW201124418A (en)	2011-07-16
US20180118754A1 (en)	2018-05-03
AU2010309832B2 (en)	2014-01-30
AU2010309832A1 (en)	2012-04-19
NZ599162A (en)	2013-08-30
JP2013508334A (ja)	2013-03-07
EA020330B1 (ru)	2014-10-30
IL219248A0 (en)	2012-06-28
MY164731A (en)	2018-01-30
ZA201203662B (en)	2013-10-30
PE20121390A1 (es)	2012-10-15
ME02064B (me)	2015-05-20
IL219248A (en)	2015-02-26
CA2777902C (en)	2018-03-06
HK1173728A1 (en)	2013-05-24
SI2491037T1 (sl)	2014-08-29
US9321773B2 (en)	2016-04-26
DK2491037T3 (da)	2014-07-21
EP2491037A1 (en)	2012-08-29
CY1116057T1 (el)	2017-02-08
CL2012000981A1 (es)	2012-08-31
ES2477270T3 (es)	2014-07-16
MX2012004525A (es)	2012-05-29
JP5889792B2 (ja)	2016-03-22
EA020330B3 (ru)	2015-07-30
US20140249164A1 (en)	2014-09-04
ECSP12011805A (es)	2012-06-29
GB0918249D0 (en)	2009-12-02
EP2491037B1 (en)	2014-04-30
CA2777902A1 (en)	2011-04-28
NI201300035A (es)	2013-06-04
UA108743C2 (uk)	2015-06-10
PH12012500620A1 (en)	2015-03-20
US9834560B2 (en)	2017-12-05
CN102712645B (zh)	2015-10-21
KR20120114225A (ko)	2012-10-16
EA201270575A1 (ru)	2012-09-28
BR112012009214A2 (pt)	2016-08-16
HRP20140599T1 (hr)	2014-09-12

Publication	Publication Date	Title
SMT201400086B (it)	2014-09-08	Derivati chinazolin-4(3H)-one usati come inibitoridi PI3 chinasi
SMT201500076B (it)	2015-07-09	Derivati di chinazolin-4(3H)-one utilizzati come inibitori della PI3 chinasi
SMAP200800048A (it)	2008-08-13	Derivati pirimidinici utilizzati come inibitori dip13-chinasi
EP2167092A4 (en)	2012-07-25	QUINAZOLINE DERIVATIVES AS INHIBITORS OF PI3 KINASE
EP2498607A4 (en)	2013-06-19	Kinase Inhibitors
EP2493313A4 (en)	2013-05-15	Kinase Inhibitors
DK2406253T3 (da)	2013-08-12	Benzofuranylderivater anvendt som glucokinase-inhibitorer
BRPI0912294A2 (pt)	2015-10-20	compostos de triazina como inibidores de pi3 quinase e de mtor
BRPI1011046A2 (pt)	2016-03-15	derivados de isoquinolin-1 (2h)-ona como inibidores de parp-i
EP2558099A4 (en)	2013-07-17	Kinase inhibitors
ES2598358T8 (es)	2017-02-13	Derivados de quinolina como inhibidores de PI3K quinasa
EP2632898A4 (en)	2014-04-02	HETEROCYCLIC TYROSINE KINASE HEMMER
PL2504336T3 (pl)	2016-10-31	Nowe pochodne naftyrydynowe i ich zastosowanie jako inhibitorów kinaz
RS55662B1 (sr)	2017-06-30	Derivati benzimidazola kao inhibitori pi3 kinaze
EP2211615A4 (en)	2010-10-13	PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
BR112013008527A2 (pt)	2016-07-12	derivados de pirazolo-quinazolina substituídos como inibidores de cinase
EP2515657A4 (en)	2013-07-03	Tyrosine kinase inhibitor
BRPI0906838A2 (pt)	2015-07-14	Pirimidinas como inibidores de quinase
SMAP200900065A (it)	2009-09-07	Derivati ciclizzati come inibitori di eg-5
DK2318378T3 (da)	2013-11-18	Quinazolin-derivater
SMT201600076B (it)	2016-04-29	Derivati di 2-osso-1-pirrolidinil imidazotiadiazolo
ZA201104873B (en)	2012-07-25	Quinazolinone derivatives useful as vanilloid antagonists
SMT201400080B (it)	2014-09-08	Derivati di pirazinoossazepina
ES2439793T9 (es)	2016-03-10	Compuestos de pirimidina, su uso como inhibidores de la mTOR quinasa y de la PI3 quinasa, y su síntesis
BR112012010524A2 (pt)	2017-12-12	compostos derivados de quinazolina